Sugi Predict

Sugi Predict / Compounds / SCHEMBL20009190

SCHEMBL20009190

SCHEMBL20009190

CC(C)(C)OC(=O)N1C[C@H](N(OCc2ccccc2)C(=O)OC(C)(C)C)CC[C@H]1C(=O)Nc1cccc2cccnc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ UBE2M P61081 1/20 0.42
▸ DCUN1D1 Q96GG9 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ TSHR P16473 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ EPHX2 P34913 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TNKS O95271 1/20 0.38
▸ TNKS2 Q9H2K2 1/20 0.38
▸ HIF1A Q16665 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.37
▸ HDAC4 P56524 3/20 0.37
▸ HDAC1 Q13547 3/20 0.37
▸ HDAC6 Q9UBN7 3/20 0.37
▸ HCRTR1 O43613 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19990855 0.95 UBE2M (0.42) POLBKDM4EUBE2MDCUN1D1TSHR
SCHEMBL20009193 0.85 UBE2M (0.38) POLBKDM4EUBE2MDCUN1D1TSHR
SCHEMBL20009191 0.84 UBE2M (0.37) POLBKDM4EUBE2MDCUN1D1TSHR
SCHEMBL20009194 0.82 UBE2M (0.37) POLBKDM4EUBE2MDCUN1D1TSHR
SCHEMBL19990942 0.81 UBE2M (0.40) POLBUBE2MDCUN1D1MEN1KMT2A
SCHEMBL19990693 0.80 L3MBTL1 (0.43) KDM4EL3MBTL1
SCHEMBL19990701 0.80 UBE2M (0.39) POLBUBE2MDCUN1D1MEN1KMT2A
SCHEMBL23927098 0.79 UBE2M (0.42) UBE2MDCUN1D1MEN1KMT2ATSHR
SCHEMBL19990700 0.78 UBE2M (0.39) UBE2MDCUN1D1TSHRGAAEPHX2
SCHEMBL10058233 0.77 SSTR4 (0.39) MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109843894-B Beta-lactamase inhibitors 诺华股份有限公司 2022-02-08 — — CN disclosed
EP-3698796-B1 PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS NOVARTIS AG (CH) 2021-10-27 — — EP disclosed
EP-3698796-B1 PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS NOVARTIS AG (CH) 2021-10-27 — — EP disclosed
EP-3698796-A1 PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS Novartis AG (CH) 2020-08-26 — — EP disclosed
US-20190177324-A1 BETA-LACTAMASE INHIBITORS NOVARTIS AG (CH) 2019-06-13 — — US disclosed
US-20180086762-A1 BETA-LACTAMASE INHIBITORS NOVARTIS AG (CH) 2018-03-29 — — US disclosed
US-20180086762-A1 BETA-LACTAMASE INHIBITORS NOVARTIS AG (CH) 2018-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190177324-A1 BETA-LACTAMASE INHIBITORS MGAM, LCT, GAA POLB 527/4885KDM4E 2244/4885UBE2M 752/4885
US-20180086762-A1 BETA-LACTAMASE INHIBITORS MGAM, LCT, GAA POLB 527/4885KDM4E 2244/4885UBE2M 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.